Previous Close | 25.58 |
Open | 26.68 |
Bid | 26.34 x 300 |
Ask | 26.48 x 200 |
Day's Range | 26.08 - 27.34 |
52 Week Range | 4.82 - 27.66 |
Volume | |
Avg. Volume | 1,170,413 |
Market Cap | 2.529B |
Beta (5Y Monthly) | 0.77 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
President and CEO Sarah Boyce of Avidity Biosciences Inc (NASDAQ:RNA) sold 28,000 shares of the company on April 2, 2024, according to a recent SEC filing.
Michael Maclean, Chief Financial Officer of Avidity Biosciences Inc (NASDAQ:RNA), sold 40,000 shares of the company on March 13, 2024, according to a recent SEC filing.
Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.